Related Experiment Video
Updated: Jan 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Tumor growth rate for prognostic stratification and treatment optimization in unresectable hepatocellular carcinoma
Guobin Chen1,2,3, Meixia Wang1, Xing Huang1
1Department of Hepatic Oncology, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, 361015, China.
Background:
Tumor growth rate (TGR) is a dynamic biomarker for evaluating therapeutic response and prognosis in unresectable hepatocellular carcinoma (uHCC) with triple therapy, yet its clinical utility and role in guiding treatment optimization require further validation.
Methods:
This study included 68 uHCC patients receiving transarterial chemoembolization (TACE) with systemic combination therapy. Propensity score matching (PSM) was applied to balance baseline confounders. Cubic spline models explored nonlinear associations between TGR and survival risk and found the ideal cut-off points. Kaplan-Meier (KM) analysis compared overall survival (OS) and progression-free survival (PFS) between TGR subgroups, Cox multivariate regression evaluated the independent prognostic value of TGR.
Results:
Cox analysis confirmed TGR0 as an independent prognostic factor for OS (hazard ratio (HR) 1.035, 95% confidence interval (CI): 1.013-1.057, p = 0.020) and PFS (HR 1.033, 95%CI: 1.014-1.053, p = 0.001). After stratified for TGR0/TGR1 and matched, the low-TGR0 group showed significantly longer median OS (not reached vs. 13.09 months, p = 0.002) and PFS (12.11 vs. 4.38 months, p = 0.006) than the high-TGR0 group. In the subgroup analysis, after propensity score matching(PSM), the low-TGR1 group demonstrated a more favorable prognosis compared with high-TGR1(mOS: not reached vs. 16.97 months, p = 0.024; mOS1: not reached vs. 11.78 months, p = 0.022).
Conclusions:
Dynamic TGR monitoring identifies heterogeneous therapeutic responses, guiding timely personalized treatment adjustments and prognostic stratification in uHCC.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
05:31Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Gene Therapy
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Rate-Determining Steps
In a multistep reaction mechanism, one of the elementary steps progresses significantly slower than the others. This slowest step is called the rate-limiting step (or rate-determining step). A reaction cannot proceed faster than its slowest step, and hence, the rate-determining step limits the overall reaction rate.
The concept of rate-determining step can be understood from the analogy of a 4-lane freeway with a short-stretch of traffic-bottleneck caused due to...